<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145076</url>
  </required_header>
  <id_info>
    <org_study_id>14/LO/0663</org_study_id>
    <nct_id>NCT04145076</nct_id>
  </id_info>
  <brief_title>Brain Response to Serotonergic Medications in ASD</brief_title>
  <official_title>Can Brain Activation and Connectivity Predict Treatment Response to Two Serotonergic Medications (Citalopram and Tianeptine) in Subjects With Autism Spectrum Disorders (ASD)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates brain response to single acute dose of citalopram, tianeptine, and
      placebo in males with and without autism spectrum disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is increasing evidence that the serotonin (5-HT) system is implicated in autism
      spectrum disorder (ASD), with the standard treatment for depression and anxiety in both the
      general population and ASD includes targeting the 5-HT system with selective serotonin
      reuptake inhibitors (SSRIs) citalopram. Some individuals with ASD have a good treatment
      response but others do not. Tianeptine, which has a different mechanism of action to SSRIs,
      is also an effective antidepressant. As it is unlikely that all individuals with ASD will
      respond to the same treatment, the investigators aim to conduct a pharmacological magnetic
      resonance imaging (phMRI) investigation to elucidate the neural mechanisms underlying the
      response to citalopram and tianeptine in ASD. The investigators are inviting 50 male adults
      with ASD and 50 male adults without ASD. Each participant receives each drug once (20 mg
      citalopram, 12.5 mg tianeptine, or placebo) and MRI is used to obtain measures of brain
      biochemistry, activity, and connectivity. The investigators also acquire data from
      questionnaires, electroencephalography, neurocognitive tests and blood samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Repeated-measures cross-over study, where each subject receives each of three pharmacological probes once (order of drug administration was pseudorandomised).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators are blinded to the drug condition.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain excitation and inhibition response to pharmacological stimulation as assessed by magnetic resonance spectroscopy</measure>
    <time_frame>In the months 1-2 following the last day of scanning</time_frame>
    <description>The measure of brain excitation and inhibition response to placebo, citalopram, and tianeptine includes the following:
Assessment of the ratio of brain excitation and inhibition (measured as the balance of excitatory and inhibitory neurotransmitters) using proton magnetic resonance spectroscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activation response to pharmacological stimulation as assessed by functional magnetic resonance imaging</measure>
    <time_frame>In the months 3-4 following the last day of scanning</time_frame>
    <description>The measure of brain activation response to placebo, citalopram, and tianeptine includes the following:
Assessment of the blood-oxygen-level-dependent activation during tasks using functional magnetic resonance imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain connectivity response to pharmacological stimulation as assessed by resting-state functional magnetic resonance imaging</measure>
    <time_frame>In the months 5-6 following the last day of scanning</time_frame>
    <description>The measure of brain connectivity response to placebo, citalopram, and tianeptine includes the following:
Assessment of the regional homogeneity during resting-state using functional magnetic resonance imaging.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo, Citalopram, Tianeptine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Placebo, Citalopram, Tianeptine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Tianeptine, Citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Placebo, Tianeptine, Citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citalopram, Placebo, Tianeptine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Citalopram, Placebo, Tianeptine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citalopram, Tianeptine, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Citalopram, Tianeptine, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tianeptine, Placebo, Citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Tianeptine, Placebo, Citalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tianeptine, Citalopram, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Tianeptine, Citalopram, Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two oral doses of placebo.</description>
    <arm_group_label>Citalopram, Placebo, Tianeptine</arm_group_label>
    <arm_group_label>Citalopram, Tianeptine, Placebo</arm_group_label>
    <arm_group_label>Placebo, Citalopram, Tianeptine</arm_group_label>
    <arm_group_label>Placebo, Tianeptine, Citalopram</arm_group_label>
    <arm_group_label>Tianeptine, Citalopram, Placebo</arm_group_label>
    <arm_group_label>Tianeptine, Placebo, Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Single oral dose of citalopram (20mg) and single oral dose of placebo.</description>
    <arm_group_label>Citalopram, Placebo, Tianeptine</arm_group_label>
    <arm_group_label>Citalopram, Tianeptine, Placebo</arm_group_label>
    <arm_group_label>Placebo, Citalopram, Tianeptine</arm_group_label>
    <arm_group_label>Placebo, Tianeptine, Citalopram</arm_group_label>
    <arm_group_label>Tianeptine, Citalopram, Placebo</arm_group_label>
    <arm_group_label>Tianeptine, Placebo, Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tianeptine</intervention_name>
    <description>Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.</description>
    <arm_group_label>Citalopram, Placebo, Tianeptine</arm_group_label>
    <arm_group_label>Citalopram, Tianeptine, Placebo</arm_group_label>
    <arm_group_label>Placebo, Citalopram, Tianeptine</arm_group_label>
    <arm_group_label>Placebo, Tianeptine, Citalopram</arm_group_label>
    <arm_group_label>Tianeptine, Citalopram, Placebo</arm_group_label>
    <arm_group_label>Tianeptine, Placebo, Citalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intelligence Quotient (IQ) above 70

          -  Has capacity and is capable of giving written informed consent

          -  Able to read, comprehend and record information written in English

          -  Bodyweight of &lt;120 kg and BMI within the range 18.5 - 33 kg/m2 (inclusive).

          -  Not taking medication directly affecting gamma-aminobutyric acid (GABA)
             neurotransmission for at least the past 4 weeks

          -  Not taking medication directly affecting the serotonergic system for at least the past
             4 weeks

          -  ASD only: Diagnosis of Autism Spectrum Disorder (ICD 10-R criteria, confirmed using
             the Autism Diagnostic Interview (ADI) and/or ADOS) including atypical autism

          -  ASD only: Being recommended drug therapy for symptoms of depression and/or anxiety

          -  Controls only: No diagnosis of Autism Spectrum Disorder (ICD 10-R criteria, confirmed
             using the ADI and/or ADOS)

          -  Controls only: No diagnosis of major depressive disorder according to the Diagnostic
             and Statistical Manual of Mental Disorders (DSM) IV or ICD 10.

        Exclusion Criteria:

          -  Current risk of self-harm

          -  Acute risk of suicidality (e.g., current suicidal ideations)

          -  Age &lt; 18 years or &gt; 60 years old.

          -  Taking medication directly affecting the serotonergic system (e.g. SSRIs, Tricyclic
             antidepressants)

          -  Taking medication directly affecting GABA neurotransmission (e.g. antiepileptic drugs,
             and benzodiazepines)

          -  Taking antipsychotic medication or medication for attention deficit hyperactivity
             disorder (ADHD) for the past 4 weeks

          -  History of dependence to alcohol or substances of abuse (excluding nicotine)

          -  Major mental illness (e.g. psychosis), or a learning disability (mental retardation)

          -  Needle phobia

          -  Medical/genetic disorder associated with ASD

          -  Diagnosed and treated for hyperkinesis or Tourette's syndrome

          -  Allergy to food colouring
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne McAlonan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Declan Murphy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nichol Wong, PhD</last_name>
    <phone>+44 (0)2078480124</phone>
    <email>nichol.wong@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grainne McAlonan, PhD</last_name>
    <phone>+44 (0)2078480831</phone>
    <email>grainne.mcalonan@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichol Wong, PhD</last_name>
      <phone>+44 (0)2078480124</phone>
      <email>nichol.wong@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Grainne McAlonan</investigator_full_name>
    <investigator_title>Deputy head of department</investigator_title>
  </responsible_party>
  <keyword>citalopram</keyword>
  <keyword>tianeptine</keyword>
  <keyword>pharmacological imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Tianeptine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

